Musely / The Body Cream
VANISH FORMULA
A compounded 12% hydroquinone body cream sold on subscription. That is three times the standard prescription strength, on the largest surface area on the body, for as long as you keep paying. The number is not on the product page.
There is a real reason to hesitate. Read the finding before you buy.
ASSESSED ON 75% OF THE MODEL. 2 CRITERIA LEFT UNSCORED — SEE SCORING FOR WHY.
Prescription product — you complete a consultation before anything ships. Read the 12% finding above first.
The verdict
The active combination is the right one. Hydroquinone plus a retinoid is the best-evidenced approach to stubborn hyperpigmentation there is, and putting it behind a prescriber rather than selling it over the counter is the correct side of the line.
The doses are the problem. Hydroquinone is compounded at 12% — three times the 4% that prescription products are conventionally written at, and above the threshold the ochronosis literature repeatedly flags. Meanwhile the tretinoin sits at 0.01%, below the concentrations tretinoin trials are run at, and the glycolic acid at 1% is not doing meaningful exfoliation at any pH.
So the formula leans almost entirely on one very strong tyrosinase inhibitor, applied to body-sized surface areas, on an open-ended monthly subscription. Those three factors — high concentration, large area, extended duration — are precisely the three the safety literature lists together.
None of that appears on the page where you buy it. The concentrations live in a help-centre article. The size of the bottle is not published anywhere we could find, which makes cost per application impossible to calculate. For a site that scores disclosure, that is where most of the damage is done.
- Prescription-gated with a prescriber consultation, which is the correct handling for hydroquinone at any strength.
- Opaque pump packaging and a deliberate antioxidant system — sodium bisulfite, BHT and ascorbic acid — to slow hydroquinone oxidation.
- The active pairing itself is the best-evidenced approach to stubborn pigmentation available.
- Formula variants are published for different concerns, and the KP and Fade versions drop hydroquinone entirely.
- A stated results guarantee and a monthly cadence that is cheaper than repeated in-office treatment.
- 12% hydroquinone — triple the conventional prescription strength — with no published trial support for the increment.
- Concentrations absent from the product page; discoverable only via a support article.
- Tretinoin at 0.01% and glycolic acid at 1% are both below functionally meaningful levels.
- Fill volume unpublished, so cost per application cannot be calculated.
- Headline efficacy figures come from an uncontrolled, unblinded, self-reported customer survey.
- Subscription framing encourages continuous use of an active that guidance says should be cycled.
- Compounded preparations are not FDA-evaluated for safety or efficacy the way an approved drug is.
Every active, assessed
| ACTIVE | CONC. | BENCHMARK | ASSESSMENT |
|---|---|---|---|
| HydroquinoneTyrosinase inhibitor — blocks melanin synthesis | 12% | 4% is the conventional prescription strength; 2% was the old OTC ceiling | Three times the usual prescription concentration. There is no published trial base establishing that 12% outperforms 4%, and the systematic review literature associates concentrations above 4% with a higher share of reported ochronosis cases. |
| TretinoinRetinoid — accelerates turnover, aids hydroquinone penetration | 0.01% | 0.025%–0.1% in the trial literature; Tri-Luma uses 0.05% | Below the range tretinoin efficacy trials are conducted at. At this level it is best read as a penetration aid for the hydroquinone rather than an independently active retinoid dose. |
| Glycolic AcidAlpha hydroxy acid — surface exfoliation | 1% | 4%–12% for functional exfoliation, and only below pH 4 | Decorative at this concentration. Nothing measurable happens to corneocyte adhesion at 1%, and the base is not formulated to a low pH. |
| Hyaluronic AcidHumectant | NOT STATED | 0.1%–2% | Listed on the marketing page for the product family. The published Vanish formula does not state a concentration; treat it as a vehicle component, not an active. |
Scoring
- EVIDENCE FOR THE ACTIVEWEIGHT 30%55/100
Hydroquinone plus tretinoin for hyperpigmentation is grade-A territory — it is the basis of the Kligman formula and of the only FDA-approved hydroquinone product. But the trial base sits at 4% hydroquinone with 0.05% tretinoin. This formula is at 12% and 0.01%. The actives are evidenced; these doses are not.
- FORMULATION INTEGRITYWEIGHT 20%60/100
Genuinely competent on the part that matters most for hydroquinone: an opaque pump rather than a jar, and a stack of antioxidants — sodium bisulfite, BHT, ascorbic acid — specifically there to slow oxidation. Marked down because two of the four named actives are dosed below the level at which they do anything.
- DISCLOSUREWEIGHT 15%25/100
The product page names four actives and no concentrations. The 12% figure is findable only in a support-centre article about formula variants. Container size is not published, so cost per application cannot be worked out. A 12% hydroquinone is exactly the number that belongs above the fold.
- TOLERANCE IN USEWEIGHT 15%NOT ASSESSED
Not assessed. We have not run this through the panel, and we will not infer a tolerance score from a vendor's own satisfaction survey. The brand itself lists dry skin, peeling, temporary hyperpigmentation and irritation as reported effects.
- TEXTURE & WEARWEIGHT 10%NOT ASSESSED
Not assessed. Requires the product in hand over the full trial window.
- COST PER APPLICATIONWEIGHT 10%30/100
$49 a month on a rolling subscription with a two-month minimum. Because the fill volume is not published and the instruction is to treat body-sized areas nightly, cost per application is not computable from published information. Unknowable cost scores badly by construction.
What it is
The Body Cream is a compounded prescription cream sold by Musely, a telehealth company. You complete an online consultation, a prescriber reviews it, and a compounding pharmacy makes up a cream to one of several published formulas. It is billed at $49 a month, starting with a two-month supply, and it is marketed for dark spots, sun damage, acne scarring and hyperpigmentation on the body rather than the face.
The product page names the actives as hydroquinone, tretinoin, glycolic acid and hyaluronic acid. It does not state how much of any of them is in the tube. That information exists — it is in Musely's own support centre, in an article listing the formula variants — but it is not where you buy the product.
The finding: 12%
The Vanish formula is compounded at hydroquinone 12%, tretinoin 0.01% and glycolic acid 1%. The hydroquinone figure is the one that matters, and it is worth being precise about why.
The trial literature, the approved product and the old OTC ceiling all sit at or below 4%.
Hydroquinone works. It is a competitive tyrosinase inhibitor and it is the most effective topical depigmenting agent in general use. The question is not whether it works but whether tripling the dose buys anything, and whether it costs anything.
On the first: we could find no published controlled trial establishing that 12% outperforms 4% for hyperpigmentation. The dose–response curve for hydroquinone is not documented to keep climbing past the standard concentration; what is documented is that irritation rises with it.
On the second: exogenous ochronosis — a paradoxical blue-black darkening of the treated skin, difficult to reverse — is the specific adverse outcome the hydroquinone literature tracks. A 2022 systematic review in the International Journal of Dermatology found reported cases clustered at concentrations above 4%. The risk factors repeatedly named alongside concentration are large treated surface area, prolonged duration of use, and deeper skin tones.
This is a body cream. Large surface area is not a misuse case here — it is the product category. It is sold on a rolling monthly subscription, which is a commercial structure built around prolonged duration. And it is compounded at three times the conventional strength. Concentration, area and duration are the three factors the literature lists together, and this product's design touches all three at once.
That is not a claim that this product causes ochronosis, and we are not making one. It is an observation that the product's own design sits at the intersection of the three variables the safety literature asks you to keep an eye on — and that a buyer cannot weigh that from the product page, because the product page does not tell them the concentration.
The other two actives are underdosed
Tretinoin appears at 0.01%. Tretinoin efficacy trials are run at 0.025% to 0.1%; Tri-Luma, the only FDA-approved hydroquinone combination product, uses 0.05%. At 0.01% the tretinoin is best understood as a penetration enhancer for the hydroquinone — thinning the stratum corneum, raising delivery — rather than as a retinoid dose that will do anything for texture or collagen on its own.
Glycolic acid appears at 1%. Functional exfoliation with glycolic acid needs both concentration — typically 4% and up — and a pH below about 4. At 1%, in a base that is not formulated acidic, it is on the label rather than in the mechanism.
Marketed as a four-active formula, this is functionally a very high-dose hydroquinone monotherapy with a penetration aid. That framing changes how you should think about the risk, because all the load is on the one molecule with the meaningful safety file.
The 74% figure
The most prominent number on the product page is that 74% of patients saw visible improvement by day 30, rising to 81% by day 60. The stated source is a 60-day consumer study in which 17,856 patients logged results at days 7, 30 and 60. Satisfaction is given as 66% at day 30 and 78% at day 60.
17,856 is a very large number of people, and it is doing a lot of persuasive work. It is worth separating sample size from study design, because they are not the same thing and only one of them is impressive here.
A large uncontrolled survey of people who paid for a treatment, asking them whether they think it worked, cannot separate the drug from expectation, from the sun avoidance they started at the same time, or from regression to the mean. It is a customer satisfaction measure. Presented next to a percentage sign and the word 'study', it reads as a clinical result, and it is not one.
This is not a claim that the product does not work — with 12% hydroquinone on board, it very likely does something visible. It is a claim that this particular figure is not evidence of it, and that a company able to survey 17,856 patients is a company able to run a controlled arm.
The vehicle, which is the good part
Hydroquinone oxidises. Once it does, it is inactive and the product discolours. Judged on that specific problem, this formulation is competently built.
- Sodium bisulfite and butylated hydroxytoluene are both in the inactive list as antioxidants, which is exactly what a hydroquinone preparation needs.
- Ascorbic acid appears in the published inactive list, adding further reducing capacity.
- The packaging is an opaque pump cylinder rather than a jar — the right call, and one a lot of pigment products get wrong.
- Squalane, petrolatum, cocoa seed butter and cetyl alcohol give an occlusive, emollient base, which is sensible under a drying active stack.
- Titanium dioxide is present, likely as an opacifier for the base rather than as a UV filter — do not read it as sun protection.
There are things in the inactive list a sensitive user should know about: ethyl alcohol, propylene glycol, sodium lauryl sulfoacetate and BHT are all recognised irritants or sensitisers for some people. On a prescription product used under supervision that is a reasonable trade; it is still worth reading before you put it on a large area.
The commercial structure
Two things about how this is sold affect how it should be used, and they pull in opposite directions.
The first is that prescription gating is correct. Since the CARES Act took effect in September 2020, over-the-counter hydroquinone has been off the US market; hydroquinone is now available either through an approved new drug application or as a patient-specific compounded prescription. Musely operates in the second category, legitimately. Putting a prescriber between the customer and a 12% depigmenting agent is the right architecture.
The second is that a rolling monthly subscription is a strange delivery mechanism for a drug that standard guidance says should be used in time-limited courses with breaks. The default behaviour a subscription produces is continuous use. The default behaviour hydroquinone guidance asks for is the opposite. Whatever the prescriber says at consultation, the billing model is pushing the other way.
A compounded preparation is made to a prescription for an individual patient. It has not gone through the FDA review that an approved drug goes through, and it is not evaluated for safety, efficacy or manufacturing consistency in the same way. That is lawful and routine — it is also a meaningful difference from Tri-Luma, and it is not something the marketing draws attention to.
If you are going to use it
- Ask the prescriber directly for the concentration you have been written, and ask why 12% rather than 4%. Get the answer in writing.
- Agree a stop date at the start. Hydroquinone is conventionally used in courses of a few months, not indefinitely.
- Treat a defined area. Do not extend it across a whole back or both legs because you have cream left.
- Use daily broad-spectrum sun protection on the treated area without exception. Depigmenting skin and then exposing it to UV is the fastest way to undo the result and provoke rebound.
- Photograph the area under fixed lighting at the start, monthly, from the same distance. It is the only way you will know whether it is working.
- Stop and contact the prescriber immediately if the treated area darkens, greys or develops a bluish cast rather than lightening.
- Do not use it if there is any chance you are pregnant.
Where we stand
We have not put this through the panel, so two of our six criteria are unscored and the total below is out of the 75% of the model that a desk review can honestly reach. We are not going to manufacture a tolerance figure from a vendor's satisfaction survey.
What we can assess, we have. The active pairing is sound and the packaging is right. The concentration is three times the evidenced dose with nothing published to justify the increment; two of the four advertised actives are below working levels; the headline efficacy figure is a satisfaction survey; and the single most important fact about the product — that it contains 12% hydroquinone — is not on the page that sells it.
That last point is the one that decides the score. A buyer who knows they are applying 12% hydroquinone to a large area every night can have a sensible conversation with a prescriber about whether that is a good idea. A buyer who does not know cannot.
Who this is for
- Someone with established, stubborn body hyperpigmentation who has already failed lower-strength options.
- Someone who will actually use it under prescriber supervision and stop when told to.
- Someone treating a defined area — not resurfacing a whole back or both legs indefinitely.
- Someone who will pair it with daily broad-spectrum sun protection, without which the whole exercise is self-defeating.
- You are pregnant or breastfeeding. Tretinoin is contraindicated.
- You want to treat a large surface area continuously — that is the exact risk profile the ochronosis literature describes.
- You have a deeper skin tone and are not being actively monitored; reported ochronosis risk is concentrated here.
- You are unwilling to cycle off. Guidance for hydroquinone is time-limited courses, not indefinite subscription use.
- You are looking for a first-line treatment. Start lower — azelaic acid, or 4% hydroquinone — before 12%.
Prescription product — you complete a consultation before anything ships. Read the 12% finding above first.
This is an editorial assessment of published information about a prescription product. It is not a diagnosis, not a prescription and not a substitute for your own prescriber. Hydroquinone and tretinoin are drugs. Decisions about them belong with a clinician who has seen your skin.
Sources
- S-01Musely — The Body Cream product page Price, claims, directions, actives named without concentrations, 74%/81% figures, 60-day consumer study description.
- S-02Musely Help Centre — formulas for The Body Cream Source of the Vanish formula concentrations: hydroquinone 12%, tretinoin 0.01%, glycolic acid 1%.
- S-03SkinSort — Musely FaceRx The Body Cream, Vanish Published inactive ingredient list used for the vehicle assessment.
- S-04FDA — protecting consumers from potentially harmful OTC skin lightening products Regulatory status of hydroquinone in the United States.
- S-05Practical Dermatology — Hydroquinone in 2021 CARES Act effect from September 2020; Tri-Luma as the only approved hydroquinone NDA; compounding carve-out.
- S-06Ishack et al. — Exogenous ochronosis associated with hydroquinone: a systematic review (Int J Dermatol, 2022) Distribution of reported ochronosis cases by hydroquinone concentration.
- S-07Medical News Today — Musely review Independent coverage of the Musely telehealth model.